Point-of-care testing
11 articles
MSF and Partners Protest Medical Test Maker Cepheid and Danaher at International AIDS Conference
Time for $5 Campaign demands Cepheid reduce price of HIV, TB and hepatitis C tests to $5 each. More
Barriers and Enablers to Point-Of-Care HCV Testing in a Needle and Syringe Program in Canada
Using an intersectionality lens to explore barriers and enablers to hepatitis C point-of-care testing: a qualitative study among people who inject drugs and service providers More
Point-of-Care HCV RNA Test Could Expedite Diagnosis, Treatment in High-Risk Settings
Findings support the feasibility and clinical performance of Xpert HCV, the first FDA-approved point-of-care test for diagnosing HCV, in a nonclinical justice setting. More
‘Time for $5’ Campaign Delivers 206,937 Signatures to Danaher Demanding a $5 Price for Their Medical Tests
US test maker Cepheid and parent corporation Danaher have ignored global calls for price reductions and have broken their promise from one year ago to be transparent about what it costs to make their medical tests. More
Hidden Costs: GeneXpert Tests and Danaher’s Delayed Audit
A technical brief makes recommendations to Danaher, as well as global health actors and governments, to ensure the audit is conducted in a timely, rigorous and transparent manner. More
